AstraZeneca Drug Cuts COPD Exacerbations in Phase III Trials
WILMINGTON, DE — AstraZeneca (NYSE: AZN) said its experimental drug tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease in two Phase III trials, according to results from …
AstraZeneca Drug Cuts COPD Exacerbations in Phase III Trials Read More